Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 91Lysosomal Storage Disorders ResearchGlycogen Storage Diseases and MyoclonusVirus-based gene therapy research

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Pompe disease gene therapy

Open access

Abstract

Pompe disease is an autosomal recessive metabolic myopathy caused by the deficiency of the lysosomal enzyme acid alpha-glucosidase and results in cellular lysosomal and cytoplasmic glycogen accumulation. A wide spectrum of disease exists from hypotonia and severe cardiac hypertrophy in the first few months of life due to severe mutations to a milder form with the onset of symptoms in adulthood. In either condition, the involvement of several systems leads to progressive weakness and disability. In early-onset severe cases, the natural history is characteristically cardiorespiratory failure and death in the first year of life. Since the advent of enzyme replacement therapy (ERT), the clinical outcomes have improved. However, it has become apparent that a new natural history is being defined in which some patients have substantial improvement following ERT, while others develop chronic disability reminiscent of the late-onset disease. In order to improve on the current clinical outcomes in Pompe patients with diminished clinical response to ERT, we sought to address the cause and potential for the treatment of disease manifestations which are not amenable to ERT. In this review, we will focus on the preclinical studies that are relevant to the development of a gene therapy strategy for Pompe disease, and have led to the first clinical trial of recombinant adeno-associated virus-mediated gene-based therapy for Pompe disease. We will cover the preliminary laboratory studies and rationale for a clinical trial, which is based on the treatment of the high rate of respiratory failure in the early-onset patients receiving ERT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddr174

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 4

  1. Teng, 2004, Chang Gung medical journal, 27, 379
  2. Willemsen, 1998, Nederlands tijdschrift voor geneeskunde, 142, 1388
  3. 1955, Pediatrics, 5, 715
  4. 2009, 7, 147

Cited by

See all 91

Metadata

Authors
Byrne, B. J., Falk, D. J., Pacak, C. A., Nayak, S., Herzog, R. W., Elder, M. E., Collins, S. W., Conlon, T. J., Clement, N., Cleaver, B. D., Cloutier, D. A., Porvasnik, S. L., Islam, S., Elmallah, M. K., Martin, A., Smith, B. K., Fuller, D. D., Lawson, L. A., & Mah, C. S.
Affiliations
University of Florida Health (US)
Venue
Human Molecular Genetics
Published
2011-04-15
Volume
20
Issue
R1
Pages
R61-R68
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2150843111
Cited by
91
References
69
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 10 · 2018: 7 · 2017: 4 · 2016: 7 · 2015: 14 · 2014: 8 · 2013: 12 · 2012: 11
FWCI
1.11
Type
journal article
Language
en
Open access
Locations
  • Human Molecular Genetics (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eCommons - AKU (Aga Khan University) (submittedVersion)
Funders
  • National Heart, Lung, and Blood Institute (P01HL059412, F32HL095282, P01 HL59412-06)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, P01 DK58327-03)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD052682)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
Pompe disease, gene therapy, acid alpha-glucosidase deficiency, recombinant adeno-associated virus, enzyme replacement therapy, respiratory failure, glycogen accumulation, lysosomal storage disease, preclinical research, clinical trials
MeSH terms
Dependovirus, Clinical Trials as Topic, Genetic Vectors, Glycogen, Glycogen Storage Disease Type II, Humans, Genetic Therapy, Treatment Outcome, Enzyme Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pompe disease gene therapy. https://app.cochat.ai/papers/10.1093/hmg/ddr174
The paper
Byrne, B. J., Falk, D. J., Pacak, C. A., Nayak, S., Herzog, R. W., Elder, M. E., Collins, S. W., Conlon, T. J., Clement, N., Cleaver, B. D., Cloutier, D. A., Porvasnik, S. L., Islam, S., Elmallah, M. K., Martin, A., Smith, B. K., Fuller, D. D., Lawson, L. A., & Mah, C. S. (2011). Pompe disease gene therapy. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddr174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.